Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Symbiotec Pharmalab is launching a INR 1,757 crore IPO, offering specialised pharmaceutical APIs, nutritional ingredients and complex injectable products.</li>
<li>The company has built a global presence in corticosteroid and steroid hormone APIs, with a significant share of revenue coming from international markets.</li>
<li>The IPO provides public investors access to a niche pharmaceutical manufacturing platform, but earnings sustainability depends on managing product concentration, regulatory compliance and global demand cycles.</li>
</ul>


Symbiotec Pharmalab is launching a INR 1,757 crore IPO, offering specialised pharmaceutical APIs, nutritional ingredients and complex injectable products.
The company has built a global presence in corticosteroid and steroid hormone APIs, with a significant share of revenue coming from international markets.
The IPO provides public investors access to a niche pharmaceutical manufacturing platform, but earnings sustainability depends on managing product concentration, regulatory compliance and global demand cycles.


Symbiotec Pharmalab IPO Review: A Niche Steroidal API Platform

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Event-Driven

<ul>
<li>The Closing Auction Session (CAS) kicked off on 3 August for Indian stocks that are part of the Futures &amp; Options (F&amp;O) segment of the market.</li>
<li>Daily total turnover in CAS since launch has averaged around US$128m. In comparison, global passives will need to trade around US$4bn of F&amp;O stocks at the CAS on 31 August.</li>
<li>There could be large moves in affected stocks in the lead up to the CAS on Monday, followed by more large moves at CAS, and a potential reversal on Tuesday. </li>
</ul>


The Closing Auction Session (CAS) kicked off on 3 August for Indian stocks that are part of the Futures &amp; Options (F&amp;O) segment of the market.
Daily total turnover in CAS since launch has averaged around US$128m. In comparison, global passives will need to trade around US$4bn of F&amp;O stocks at the CAS on 31 August.
There could be large moves in affected stocks in the lead up to the CAS on Monday, followed by more large moves at CAS, and a potential reversal on Tuesday. 


India: Key CAS Test on Monday as Global Index Rebalances

Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

Symbiotec Pharmalab / Equity Capital Markets

<ul>
<li>Symbiotec Pharmalab will launch its India IPO on August 24. The IPO consists of fresh issue of INR1.5B and OFS of INR16.1B. The price band is set at INR938–988.</li>
<li>The IPO subscription will close on August 27, with expected listing on September 1. At the upper price band, the company is seeking a market cap of INR62B (~$650M).</li>
<li>The company proposes to deploy an estimated amount of INR1B in FY27 for repayment of borrowings. As of March 31, 2026, total outstanding borrowings stood at INR3.9B.</li>
</ul>


Symbiotec Pharmalab will launch its India IPO on August 24. The IPO consists of fresh issue of INR1.5B and OFS of INR16.1B. The price band is set at INR938–988.
The IPO subscription will close on August 27, with expected listing on September 1. At the upper price band, the company is seeking a market cap of INR62B (~$650M).
The company proposes to deploy an estimated amount of INR1B in FY27 for repayment of borrowings. As of March 31, 2026, total outstanding borrowings stood at INR3.9B.


Symbiotec Pharmalab IPO: Global Leadership in Niche APIs to Support Sustainable Growth

APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Dr Agarwal's Health Care Ltd / Equity Capital Markets

Dr Agarwal's Health Care Ltd (8140044Z IN)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/dr-agarwal-s-health-care-ltd" target="_blank" data-smartkarma-citation="entities:43984:1" rel="noopener">Dr Agarwal's Health Care Ltd (8140044Z IN)</a> raised around US$350m in its India IPO in Jan 2025. The lockup on its pre-IPO investors is set to expire soon.</li>
<li>Dr Agarwal’s Health Care is a healthcare/hospital chain in India providing eyecare services, including surgeries; consultations, diagnoses, non-surgical treatments; and sells opticals, contact lens, accessories and eyecare related pharmaceutical products.</li>
<li>In this note, we will talk about the lockup dynamics and possible placement.</li>
</ul>



Dr Agarwal's Health Care Ltd (8140044Z IN) raised around US$350m in its India IPO in Jan 2025. The lockup on its pre-IPO investors is set to expire soon.
Dr Agarwal’s Health Care is a healthcare/hospital chain in India providing eyecare services, including surgeries; consultations, diagnoses, non-surgical treatments; and sells opticals, contact lens, accessories and eyecare related pharmaceutical products.
In this note, we will talk about the lockup dynamics and possible placement.


Dr Agarwal’s Health Care IPO Lockup - US$725m Lockup Release; PE Investors May Look to Cash Out

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

<ul>
<li>Biocon, a global biopharmaceutical company, saw Mylan exit its entire 5.64% stake through a INR 3,680 crore block deal, removing a major ownership overhang.</li>
<li>The transaction is earnings-neutral but improves liquidity and price discovery, allowing investors to refocus on FY27 biosimilar launches, generics utilisation, deleveraging and Syngene recovery.</li>
<li>With integration largely done and deleveraging underway, FY27 is the year Biocon has to prove the biosimilars-insulin-GLP-1 bet actually pays for itself.</li>
</ul>


Biocon, a global biopharmaceutical company, saw Mylan exit its entire 5.64% stake through a INR 3,680 crore block deal, removing a major ownership overhang.
The transaction is earnings-neutral but improves liquidity and price discovery, allowing investors to refocus on FY27 biosimilar launches, generics utilisation, deleveraging and Syngene recovery.
With integration largely done and deleveraging underway, FY27 is the year Biocon has to prove the biosimilars-insulin-GLP-1 bet actually pays for itself.


India

Laurus Labs is a research-driven, integrated pharmaceutical and biotechnology company specializing in Active Pharmaceutical Ingredients (APIs), generic formulations, and Contract Development and Manufacturing Organization (CDMO) services. The company is a global leader in antiretroviral (ARV) APIs and has diversified into oncology, cardiovascular, and biotechnology segments. Laurus Labs is headquartered in Hyderabad, India, and was founded in 2005.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laurus Labs (LAURUS IN)

Symbiotec Pharmalab IPO Review: A Niche Steroidal API Platform

Symbiotec Pharmalab combines leadership in steroidal APIs with complex injectables and biotech capabilities, offering global growth opportunities...

Nimish Maheshwari

India: Key CAS Test on Monday as Global Index Rebalances

CAS kicked off on 3 August and turnover has averaged US$128m. A global index rebalance on Monday will require passives to trade many multiples of...

Brian Freitas

Symbiotec Pharmalab IPO: Global Leadership in Niche APIs to Support Sustainable Growth

Symbiotec Pharmalab launches India IPO consisting of fresh issue of INR2B and OFS of INR16B. The price band is set at INR938–988. The IPO proceeds...

Tina Banerjee

Dr Agarwal’s Health Care IPO Lockup - US$725m Lockup Release; PE Investors May Look to Cash Out

TPG and Temasek are selling part of their stakes , around 11% of Dr Agarwal Health Care's existing share capital, to raise around US$183m, at a...

Akshat Shah

Biocon: Can It Be Next Laurus Labs?

Biocon sees Mylan exit its stake, improving liquidity and refocusing on upcoming launches and deleveraging to prove biosimilar bet pays off.

Sudarshan Bhandari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Symbiotec Pharmalab IPO Review: A Niche Steroidal API Platform

Symbiotec Pharmalab combines leadership in steroidal APIs with complex injectables and biotech capabilities, offering global growth opportunities...

Nimish Maheshwari

India: Key CAS Test on Monday as Global Index Rebalances

CAS kicked off on 3 August and turnover has averaged US$128m. A global index rebalance on Monday will require passives to trade many multiples of...

Brian Freitas

Symbiotec Pharmalab IPO: Global Leadership in Niche APIs to Support Sustainable Growth

Symbiotec Pharmalab launches India IPO consisting of fresh issue of INR2B and OFS of INR16B. The price band is set at INR938–988. The IPO proceeds...

Tina Banerjee

Dr Agarwal’s Health Care IPO Lockup - US$725m Lockup Release; PE Investors May Look to Cash Out

TPG and Temasek are selling part of their stakes , around 11% of Dr Agarwal Health Care's existing share capital, to raise around US$183m, at a...

Akshat Shah

Biocon: Can It Be Next Laurus Labs?

​Biocon sees Mylan exit its stake, improving liquidity and refocusing on upcoming launches and deleveraging to prove biosimilar bet pays off.

Sudarshan Bhandari

Biocon sees Mylan exit its stake, improving liquidity and refocusing on upcoming launches and deleveraging to prove biosimilar bet pays off.